UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Blinatumomab for First-Line Treatment of Children and Young Persons With B-ALL

Hodder, Angus; Mishra, Avijeet K; Enshaei, Amir; Baird, Susan; Elbeshlawi, Ismail; Bonney, Denise; Clesham, Katherine; ... Vora, Ajay; + view all (2024) Blinatumomab for First-Line Treatment of Children and Young Persons With B-ALL. Journal of Clinical Oncology , 42 (8) pp. 907-914. 10.1200/JCO.23.01392. Green open access

[thumbnail of hodder-et-al-2023-blinatumomab-for-first-line-treatment-of-children-and-young-persons-with-b-all.pdf]
Preview
Text
hodder-et-al-2023-blinatumomab-for-first-line-treatment-of-children-and-young-persons-with-b-all.pdf - Published Version

Download (667kB) | Preview

Abstract

PURPOSE: We tested whether blinatumomab (Blina) is effective as a toxicity-sparing alternative to first-line intensive chemotherapy in children and young persons (CYP) with B-ALL who were chemotherapy-intolerant or chemotherapy-resistant. METHODS: Data were collected for consecutive CYP (age 1-24 years) with Philadelphia chromosome-positive or Philadelphia chromosome-negative B-ALL who received Blina as first-line therapy. Blina was given as replacement for postremission intensive chemotherapy to patients with chemotherapy intolerance or resistance. Blina responders received further chemotherapy (Blin-CT) or first remission hematopoietic stem-cell transplant (Blin-HSCT) if indicated. Event-free survival (EFS) and overall survival (OS) of the Blin-CT group were compared with those of matched controls treated with standard chemotherapy in the UKALL 2003 trial. Events were defined as death, relapse, or secondary cancer. RESULTS: From February 2018 to February 2023, 105 patients were treated, of whom 85 were in the Blin-CT group and 20 were in the Blin-HSCT group. A majority of Blin-CT patients received Blina for chemotherapy intolerance (70 of 85, 82%), and the group had a higher-risk profile than unselected patients with B-ALL. Blina was well tolerated with only one patient having a grade 3/4-related toxicity event, and of the 60 patients who were minimal residual disease-positive pre-Blina, 58 of 60 (97%) responded. At a median follow-up of 22 months, the 2-year outcomes of the 80 matched Blin-CT group patients were similar to those of 192 controls (EFS, 95% [95% CI, 85 to 98] v 90% [95% CI, 65 to 93] and OS, 97% [95% CI, 86 to 99] v 94% [95% CI, 89 to 96]). Of the 20 in the HSCT group, three died because of transplant complications and two relapsed. CONCLUSION: Blina is safe and effective in first-line treatment of chemotherapy-intolerant CYP with ALL.

Type: Article
Title: Blinatumomab for First-Line Treatment of Children and Young Persons With B-ALL
Location: United States
Open access status: An open access version is available from UCL Discovery
DOI: 10.1200/JCO.23.01392
Publisher version: https://doi.org/10.1200/JCO.23.01392
Language: English
Additional information: This version is the version of record. For information on re-use, please refer to the publisher’s terms and conditions.
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Haematology
URI: https://discovery.ucl.ac.uk/id/eprint/10181934
Downloads since deposit
10Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item